Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin concentration in drainage fluid and blood samples of ICU patients
2015-000125-36Phase 4Completed
- Sponsor
- University Hospital Tübingen
- Start
- Mar 2016
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daptomycin in Gram-positive bacterial infection, sponsored by University Hospital Tübingen. Primary endpoints: Pharmacokinetics of daptomycin in blood and Elimination of daptomycin in drainage fluid. Started Mar 2016; status: completed.
02
Drugs
daptomycin
03
Conditions
Gram-positive bacterial infection
Beyond the preview
Go deeper on 2015-000125-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000125-36.